H. Porst

发表

Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study.

I. Goldstein, I. Eardley, E. Rubio-Aurioles, 2006, The journal of sexual medicine.

Cardiovascular outcomes among sildenafil users: results of the International Men’s Health Study

M. Mittleman, M. Maclure, F. Giuliano, 2008, International journal of clinical practice.

SOP Conservative ( Medical and Mechanical ) Treatment of

A. Salonia, A. Burnett, W. Hellstrom, 2013 .

SOP conservative (medical and mechanical) treatment of erectile dysfunction.

A. Salonia, A. Burnett, W. Hellstrom, 2013, The journal of sexual medicine.

Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study.

I. Sharlip, E. Rubio-Aurioles, H. Porst, 2006, European urology.

Standard Practice in Sexual Medicine

H. Porst, J. Buvat, 2018 .

Collaborative Review - Sexual Medicine - LUTS Critical Analysis of the Relationship Between Sexual Dysfunctions and Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

C. Roehrborn, S. Kaplan, K. McVary, 2011 .

Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.

C. Roehrborn, S. Kaplan, K. McVary, 2011, European urology.

Physicians' attitudes towards androgen replacement therapy for male and female sexual dysfunction

F. Tripodi, Y. Reisman, L. Lowenstein, 2016, International Journal of Impotence Research.

The relationship between penile deformity, age, psychological bother, and erectile dysfunction in a sample of men with Peyronie’s Disease (PD)

A. Burri, H. Porst, 2018, International Journal of Impotence Research.

The ‘effectiveness’ scale—therapeutic outcome of pharmacologic therapies for ED: an international consensus panel report

F. Montorsi, R. Munarriz, I. Goldstein, 2004, International Journal of Impotence Research.

ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunction.

C. Stief, A. Eisenhardt, W. Siffert, 2003, Urology.

Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction.

A. Wolka, J. Rajfer, D. Ralph, 2008, The journal of sexual medicine.

Chronic PDE-5 inhibition in patients with erectile dysfunction – a treatment approach using tadalafil once-daily

H. Porst, H. Büttner, K. Hell-Momeni, 2012, Expert opinion on pharmacotherapy.

[Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil].

H. Porst, H. Büttner, K. Hell-Momeni, 2009, Der Urologe. Ausg. A.

The effect of transurethral alprostadil on the quality of life of men with erectile dysfunction, and their partners. MUSE Study Group.

R. Morgan, C. Abbou, M. Hall, 1998, British journal of urology.

The Lost Penis Syndrome: A New Clinical Entity in Sexual Medicine.

G. Balercia, E. Jannini, H. Porst, 2021, Sexual medicine reviews.

The Importance of Male Ejaculation for Female Sexual Satisfaction and Function.

A. Burri, H. Porst, J. Buchmeier, 2018, The journal of sexual medicine.

Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men

C. Roehrborn, F. Schröder, F. Debruyne, 2017, BJU international.

Preliminary Validation of a German Version of the Sexual Complaints Screener for Women in a Female Population Sample

A. Burri, H. Porst, 2018, Sexual medicine.

Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.

C. Roehrborn, F. Montorsi, C. Stief, 2013, European urology.

Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors.

F. Montorsi, K. Kula, A. Aversa, 2012, Journal of andrology.

Phosphodiesterase Type-5 Inhibitors: A Critical Comparative Analysis

H. Porst, 2004 .

Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities

A. Rossi, D. Hatzichristou, H. Porst, 2015, BMC Urology.

A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review.

A. Salonia, I. Goldstein, A. Lenzi, 2014, European urology.

Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study).

F. Montorsi, I. Eardley, M. Maggi, 2011, The journal of sexual medicine.

Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study.

F. Sommer, M. Beneke, H. Porst, 2008, European urology.

Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: a randomized, double-blind, placebo-controlled study.

F. Montorsi, L. Valiquette, H. Porst, 2005, Mayo Clinic proceedings.

Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trial.

F. Montorsi, M. Beneke, H. Porst, 2004, The journal of sexual medicine.

The efficacy and safety of flexible-dose vardenafil (levitra) in a broad population of European men.

F. Montorsi, D. Hatzichristou, H. Porst, 2004, European urology.

Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction

C. Stief, M. Beneke, H. Porst, 2004, International journal of clinical practice.

Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial.

R. Rosen, F. Giuliano, H. Porst, 2003, Urology.

The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial

I. Goldstein, R. Rosen, F. Giuliano, 2001, International Journal of Impotence Research.

The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience.

H. Porst, 1996, The Journal of urology.

Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies.

M. Gacci, F. Boess, H. Porst, 2014, European urology.

Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups.

H. Porst, J. Buvat, Jay M. Young, 2003, Urology.

Sildenafil response is influenced by the G protein beta 3 subunit GNB3 C825T polymorphism: a pilot study.

S. Lenk, U. Wetterauer, A. Eisenhardt, 2003, The Journal of urology.

Restoring a Normal Sexual Response: The Ultimate Goal of Erectile Dysfunction Therapy

H. Porst, 2002 .

Premature ejaculation: results from a five-country European observational study.

D. Patrick, A. Kokoszka, F. Giuliano, 2008, European urology.

The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking.

F. Montorsi, R. Rosen, H. Porst, 2007, European urology.

Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies.

D. Cox, M. Oelke, L. Viktrup, 2013, Urology.

Prostatic Diseases and Male Voiding Dysfunction EfficacyandSafetyofTadalafil5mgOnceDaily for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Subgroup Analyses of Pooled Data From 4 Multinational, Randomized, Placebo-controlled Clinical Studies

D. Cox, M. Oelke, L. Viktrup, 2013 .

Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent International Society for Sexual Medicine criteria for lifelong premature ejaculation.

C. McMahon, H. Porst, 2011, The journal of sexual medicine.

Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of two phase 3 dapoxetine trials.

S. Bull, I. Sharlip, C. McMahon, 2010, The journal of sexual medicine.

Development and validation of the quality of erection questionnaire.

T. Symonds, V. Stecher, H. Porst, 2007, The journal of sexual medicine.

History and Epidemiology of Male Sexual Dysfunction

I. Sharlip, H. Porst, 2008 .

A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

C. Stief, M. Beneke, H. Porst, 2008, European urology.

Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy

I. Eardley, M. Thibonnier, H. Porst, 2002 .

Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil--a comparative study in 103 patients with erectile dysfunction.

H. Porst, 1998, International journal of impotence research.

P-42: Efficacy and safety of Vardenafil, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy

I. Eardley, M. Thibonnier, H. Porst, 2002 .

Vasoactive Substances in Erectile Dysfunction — A Survey of 10 Years’ Global Experience

H. Porst, 1997 .

Female partner's perception of premature ejaculation and its impact on relationship breakups, relationship quality, and sexual satisfaction.

A. Burri, F. Giuliano, C. McMahon, 2014, The journal of sexual medicine.

Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial.

F. Giuliano, S. Glina, D. Ralph, 2006, European urology.

376 WHAT IS THE THRESHOLD LEVEL OF THE PDE5 INHIBITORS' TESTOSTERONE-DEPENDENCE IN MEN? A DOUBLE BLIND PLACEBO-CONTROLED TRIAL OF TESTOSTERONE GEL ADDITION IN MEN WITH ED NON RESPONDING TO TADALAFIL 10 MG ONCE A DAY ALONE

I. Eardley, M. Maggi, H. Porst, 2009 .

A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction.

Edward D. Kim, F. Montorsi, G. Hackett, 2012, The journal of sexual medicine.

Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).

R. Quinton, K. Kurth, F. Debruyne, 2017, Journal of Sexual Medicine.

[Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors].

H. Porst, 2004, Der Urologe. Ausg. A.

An evidence‐based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation

W. Hellstrom, E. Laan, I. Sharlip, 2008, BJU international.

Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials.

C. McMahon, M. Rothman, S. Levine, 2011, The journal of sexual medicine.

International Society for Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation.

I. Goldstein, Kwangsung Park, W. Hellstrom, 2010, The journal of sexual medicine.

An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine (ISSM) ad hoc committee for the definition of premature ejaculation.

W. Hellstrom, E. Laan, I. Sharlip, 2008, The journal of sexual medicine.

Continuation and effectiveness of tadalafil once daily during a 6‐month observational study in erectile dysfunction: the EDATE study

F. Boess, H. Porst, C. Henneges, 2014, International journal of clinical practice.

Oral Pharmacotherapy of Erectile Dysfunction

H. Porst, 2008 .

Summary of the recommendations on sexual dysfunctions in men.

John Dean, David Rowland, Mario Maggi, 2004, The journal of sexual medicine.

Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.

V. Mirone, R. Secrest, L. Viktrup, 2011, European urology.

ORIGINAL RESEARCH—PHOSPHODIESTERASE INHIBITOR THERAPY FOR ED: Pharmacotherapy for Erectile Dysfunction

G. Christ, R. Kloner, C. Stief, 2004 .

Percutaneous sclerotherapy of varicoceles--an alternative to conventional surgical methods.

M. Lenz, W. Bähren, H. Porst, 1984, British journal of urology.

Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

C. Roehrborn, C. Stief, M. Oelke, 2016, European urology.

Congenital and Acquired Penile Deviations and Penile Fractures

H. Porst, 1997 .

F. Giuliano, S. Glina, D. Ralph, 2006, European urology.

Standards for clinical trials in male sexual dysfunctions.

A. Melman, H. Porst, A. Seftel, 2010, The journal of sexual medicine.

Physicians' attitude toward female genital plastic surgery: a multinational survey.

A. Salonia, A. Burri, Y. Reisman, 2014, The journal of sexual medicine.

Novel Treatment for Premature Ejaculation in the Light of Currently Used Therapies: A Review.

A. Burri, H. Porst, 2019, Sexual medicine reviews.

Case studies. A practical approach to premature ejaculation.

E. Jannini, H. Porst, 2011, The journal of sexual medicine.

Vardenafi l in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

P. Sandner, H. Porst, E. Ulbrich, 2008 .

Penile traction therapy with the new device ‘Penimaster PRO’ is effective and safe in the stable phase of Peyronie's disease: a controlled multicentre study

H. Porst, J. Romero, J. Martínez-Salamanca, 2018, BJU international.

Current Strategies in the Management of Peyronie's Disease (PD)-Results of a Survey of 401 Sexual Medicine Experts Across Europe.

A. Burri, H. Porst, 2019, The journal of sexual medicine.

Congenital and acquired penile curvatures: diagnosis and outcome with the Nesbit procedure.

H. Porst, J. Altwein, R. Mayer, 1985, Urologia internationalis.

Dynamic cavernosography: venous outflow studies of cavernous bodies.

W. Thon, H. Porst, J. Altwein, 1985, The Journal of urology.

New developments in education and training in sexual medicine.

I. Eardley, Y. Reisman, H. Porst, 2013, The journal of sexual medicine.

Genetic association study of the GNB3 C825T, the ACE I/D and the eNOS G894T polymorphisms and the risk to develop erectile dysfunction in a German ED population

U. Wetterauer, A. Eisenhardt, H. Sperling, 2010, Andrologia.

Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.

F. Montorsi, K. McVary, A. Wolka, 2009, European urology.

Patient Insight and Treatment Expectations in Erectile Dysfunction

H. Porst, 2016, European Medical Journal.

Transurethral Alprostadil with MUSETM (medicated urethral system for erection) vs intracavernous Alprostadil—a comparative study in 103 patients with erectile dysfunction

H. Porst, 1997, International Journal of Impotence Research.

Review Article THE RATIONALE FOR PROSTAGLANDIN El IN ERECTILE FAILURE: A SURVEY OF WORLDWIDE EXPERIENCE

H. Porst, 1998 .

Prostaglandin E1 and the nitric oxide donor linsidomine for erectile failure: a diagnostic comparative study of 40 patients.

H. Porst, Hartmut Porst, 1993, The Journal of urology.

Anatomy and Physiology of Erection

I. Sharlip, H. Porst, 2008 .

Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group.

R. Morgan, C. Abbou, M. Hall, 1998, British journal of urology.

[Erection and ejaculation disorders following retroperitoneal lymphadenectomy in non-seminomatous testicular tumors].

H. Porst, J. Altwein, R. Mayer, 1984, Der Urologe (Ausg. A).

A comparator trial between Sildenafil, Tadalafil and Vardenafil - Preliminar results in 150 patients

H. Porst, M. Kleingarn, S. Arnds, 2003 .

Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

P. Sandner, H. Porst, E. Ulbrich, 2008 .

Fortacin™ Spray for the Treatment of Premature Ejaculation

A. Burri, H. Porst, 2017, Urologia.

An overview of pharmacotherapy in premature ejaculation.

H. Porst, 2011, The journal of sexual medicine.

[Premature ejaculation].

H. Porst, 2009, Der Urologe (Ausg. A).

A practical approach to premature ejaculation. Introduction: the asynchronous couple.

E. Jannini, H. Porst, 2011, The journal of sexual medicine.

PREMATURE EJACULATION: RESULTS FROM A EUROPEAN OBSERVATIONAL STUDY

D. Patrick, F. Giuliano, M. Rothman, 2006 .

Results from an online survey investigating ED patients' insights and treatment expectations

A. Burri, H. Porst, 2015, International Journal of Impotence Research.

Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.

C. Roehrborn, R. Secrest, L. Viktrup, 2013, The journal of sexual medicine.

A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors.

F. Montorsi, A. Aversa, P. Perimenis, 2011, The journal of sexual medicine.

ORIGINAL RESEARCH—ED PHARMACOTHERAPY A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Once-A-Day Tadalafil in Men with Erectile Dysfunction Who Are Naïve to PDE5 Inhibitorsjsm_2353 2617..2624

F. Montorsi, A. Aversa, P. Perimenis, 2011 .

Classic Citations Cardiovascular Outcomes Among Sildenafil Users : Results of the International Men ’ s Health Study

M. Mittleman, M. Maclure, F. Giuliano, 2014 .

One‐year prophylactic efficacy and safety of pantoprazole in controlling gastro‐oesophageal reflux symptoms in patients with healed reflux oesophagitis

C. Maier, H. Koop, H. Porst, 1997, Alimentary pharmacology & therapeutics.

Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction.

S. Glina, D. Ralph, H. Zeigler, 2010, The journal of sexual medicine.

Quality of Life and Sexual Function Benefits Effects of Long-Term Testosterone Treatment: Longitudinal Results from the Registry of Hypogonadism (RHYME)

R. Quinton, K. Kurth, G. Hackett, 2017 .

Oxford School of Sexual Medicine: how are we doing?

F. Tripodi, Y. Reisman, L. Lowenstein, 2015, The journal of sexual medicine.

IMPACT OF PREMATURE EJACULATION (PE) ON FEMALE PARTNERS: RESULTS FROM A 5-COUNTRY EUROPEAN OBSERVATIONAL STUDY

D. Patrick, A. Kokoszka, F. Giuliano, 2008 .

Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.

R. Rosen, F. Giuliano, R. Shabsigh, 2006, Urology.

IC351 (tadalafil, Cialis): update on clinical experience

H. Porst, 2002, International Journal of Impotence Research.

Phosphodiesterase Type-5 Inhibitors: A Critical Comparative Analysis

H. Porst, 2004 .

Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials.

C. McMahon, M. Rothman, S. Levine, 2011, Journal of Sexual Medicine.

C. McMahon, H. Porst, 2011, The journal of sexual medicine.

A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

C. Stief, M. Beneke, H. Porst, 2008, European urology.

Reflexionen über 50 Jahre Sexualmedizin in der Urologie mit Fokus auf männliche Sexualstörungen

H. Porst, H. Porst, 2019, Aktuelle Urologie.

Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups.

H. Porst, J. Buvat, Jay M. Young, 2003, Urology.

The future of erectile dysfunction (ED).

H. Porst, 2010, Archivos espanoles de urologia.